Drug Information Journal, Vol. 25, pp. V–XVI, 1991
Printed in the USA. All rights reserved.

0092-8615/91 $3.00 + .00
Copyright © 1991 Drug Information Association Inc.

Contents
Volume 25, 1991

Volume 25, Number 1 1991

CONTENTS

Robert J. Temple	1	Access, Science, and Regulation
P. Blake **M. J. Ratcliffe**	13	Can We Accelerate Drug Development?
Alan Gelberg **George D. Armstrong** **Michael W. Dreis** **Charles Anello**	19	Technological Developments with the FDA Adverse Drug Reaction File System
Tom A. Hutchinson **A. Philip Dawid** **David J. Spiegelhalter** **Robert G. Cowell** **Sue Roden**	29	Computerized Aids for Probabilistic Assessment of Drug Safety I: A Spreadsheet Program
Tom A. Hutchinson **A. Philip Dawid** **David J. Spiegelhalter** **Robert G. Cowell** **Sue Roden**	41	Computerized Aids for Probabilistic Assessment of Drug Safety II: An Expert System
Beverly M. DeVries **George S. Hughes, Jr** **Linda S. Huyser**	49	Screening for Illicit Drug Use in Drug Development Studies
Chih-Wu Chang **John G. Caster** **Jed C. Morris** **Roger P. Nelson** **David L. Larson**	55	Automated Information Delivery in a Pharmaceutical Company
Joseph A. Tangrea **Maria Elena Adrianza** **Mary McAdams**	63	A Method for the Detection and Management of Adverse Events in Clinical Trials

Gene S. Gilbert **Naitee Ting** **Lonni Zubkoff**	81	A Statistical Comparison of Drug Safety in Controlled Clinical Trials: The Genie Score as an Objective Measure of Lab Abnormalities
Michael C. Joseph **Kathy Schoeffler** **Peggy A. Doi** **Helen Yefko** **Cindy Engle** **Erika F. Nissman**	97	An Automated COSTART Coding Scheme
Mary Ann F. Kirkpatrick	109	Factors that Motivate Healthy Adults to Participate in Phase I Drug Trials
Mickey C. Smith **Julie A. Fisher**	115	A Computerized Bibliography of Research on Medication Use Studies (MUST)
Robert M. Bell	123	Welcome and Introduction
Joyce A. Generali	125	Adverse Drug Reactions: Communications and Reporting—Hospital and Home Health Care Perspectives
G. Edward Collins	131	Adverse Drug Experience Communications and Reporting Industry Perspective: Regulations and Practice
Karen Overstreet Price **Jack M. Rosenberg** **Martha M. Rumore**	139	Fee-for-Service and Cost Justification Activities of Pharmacist-manned Drug Information Centers in the United States
J. Anne Milochik	155	Information Technologies—Challenges of the 1990s: A Company View
	161	Erratum
	I	Software Survey Section: *BBAC—Blood and Breath Alcohol Concentrations*

Volume 25, Number 2 1991

CONTENTS

The Management of Adverse Experience Information: Phase 1 Through Epidemiology

Raymond L. Herman	163	Opening Remarks
A. D. Dayan	165	The Limitations of Animal Studies: What Can and Cannot Be Predicted for Man
Michael L'E. Orme **Philip A. Routledge** **John D. Harry**	171	The Safety of Phase I Studies: A Study of Healthy Volunteer Studies in Great Britain Over a 12-Month Period
Judith Kramer LittleJohn **Deborah Otcasek Lucas** **Gail Batson-Fowler** **Suzanne Edwards**	175	Adverse Experience Collection: Perspective from a Biological Development Program
Patrick C. Waller	181	Postmarketing Surveillance: The Viewpoint of a Newcomer to Pharmacoepidemiology
M. J. S. Langman	187	Postmarketing Surveillance: The Problems of Confounded Conclusions
Susan M. Wood	191	Postmarketing Surveillance: Viewpoint from a Regulatory Authority
Margaret M. Westland	197	Coding: The Mortar in the Bricks of Data Analysis
Charles Matsumoto	201	Implementation and Use of the COSTART Dictionary at Lilly: Would We Do It Again?
Paul A. Litka	205	Labeling Development: Incorporation of Safety Information
Garth K. Graham	211	Labeling: What Should It Say, and How Should It Say It?
Jeffrey B. Margulies	217	Epidemiologic Causation in the Courtroom: Square Pegs in Round Holes?
Jan Venulet	229	APWI: Past and Present

Tom A. Hutchinson	235	Computerized Bayesian ADE Assessment
Claudio A. Naranjo **Krista L. Lanctôt**	243	Microcomputer-Assisted Bayesian Differential Diagnosis of Severe Adverse Reactions to New Drugs: A 4-Year Experience
Christian Benichou **Gaby Danan**	251	Experts' Opinion in Causality Assessment: Results of Consensus Meetings
		Additional Articles of Significant Interest
J. M. Antonello **J. F. Heyse** **D. J. Verbinski** **J. L. Ebbenga** **J. A. Trojnar** **R. L. Clark**	257	An Automated System for the Statistical Evaluation of Developmental Toxicology
Ross H. Weaver **KT Porter**	269	The Role of Information Technology in ICI Pharmaceuticals Group Medical Information Department
Robert M. Sturm	275	Strategic Uses of Information Technology in Clinical Research
Harvey Gurien	285	A Module System for the Preparation of International Dossiers, Manufacturing, and Controls (New Chemical Entities)
Jack Faricelli **Gregory L. Lazarev**	289	Analysis and Reporting Windows for Clinical Trial Information
Frank A. Adornato **Stephan J. Bachmann** **Lyse DeMontigny** **Pamela Corsentino** **Gail Lowden** **Terry Jamieson** **Linda G. Brown**	295	Worldwide Drug Planning System: An Automated System of Registration Requirements and Its Application for Regulatory Planning and Strategies
	I	Software Survey Section: PREACC

Volume 25, Number 3 July–September, 1991

CONTENTS

Part I

Articles Developed From the DIA Workshop on Statistical Issues in the Pharmaceutical Industry: Analysis of Reporting of Phase III Clinical Trials Including Kinetic/Dynamic Analysis and Bayesian Analysis

W. A. T. Archambault	305	Introduction
Lilly P. Sanathanan	307	Random Effects Modeling in Population: Kinetic/Dynamic Analysis
Lewis B. Sheiner **Raymond J. Lipicky**	319	Population PK/PD Analysis
P. I. Feder **C. T. Olson** **D. W. Hobson** **M. C. Matthews** **R. L. Joiner**	323	Statistical Analysis of Dose-Response Experiments by Maximum Likelihood Analysis and Iteratively Reweighted Nonlinear Least Squares Regression Techniques
James F. Ward **Ronald V. Nardi**	335	Using Early Drug Development Data to Design Phase III Trials
Donald A. Berry	345	Bayesian Methods in Phase III Trials
A. Lawrence Gould	369	Using Prior Findings to Augment Active-Controlled Trials and Trials With Small Placebo Groups
Michael D. Hughes	381	Practical Reporting of Bayesian Analyses of Clinical Trials
Jonathan B. Skinner	395	On Combining Studies
William H. Stewart **Kerry B. Hafner**	405	Statistical Analysis of Trough/Peak Ratios

Dennis Gillings **Gary Koch**	411	The Application of the Principle of Intention-To-Treat to the Analysis of Clinical Trials
Lilly P. Sanathanan **Carl Peck** **Robert Temple** **Ron Lieberman** **Gordon Pledger**	425	Randomization, PK-Controlled Dosing, and Titration: An Integrated Approach for Designing Clinical Trials
Gary G. Koch	433	Summary and Discussion

Part II

Statistics in the Analysis of Safety Data

Gregory G. Enas	439	Making Decisions About Safety in Clinical Trials — The Case for Inferential Statistics
William J. Huster	447	Clinical Trial Adverse Events: The Case for Descriptive Techniques
W. James Alexander	457	Adverse Events: A Classification System for Use in Clinical Trials
Gary G. Koch	461	Discussion: Statistical Perspective
	I	Software Survey Section: "**N**"

Volume 25, Number 4 October–December, 1991

CONTENTS

David A. Kessler	465	Remarks—1991 Annual DIA Meeting
A. C. Cartwright et al	471	International Harmonization and Consensus DIA Meeting on Bioavailability and Bioequivalence Testing Requirements and Standards

Articles Developed from the DIA Workshop on Integrated Safety Summary

David M. Cocchetto **Cheryl F. Graham**	483	Preface: Preparation of an Integrated Safety Summary for a New Drug Application
Robert J. Temple	485	The Regulatory Evolution of the Integrated Safety Summary
Charles Lineberry	493	Approaches to Describing Common Adverse Events in the Integrated Safety Summary
Thomas Q. Garvey III	501	Can There Really Be an Integrated Safety Summary?

Additional Articles of Significant Interest

Charles F. Curran	513	A Multidrug Patient Assistance Program
Diane Chen	523	All You Ever Wanted to Know About a CPMP Hearing—A DRA Professional's Guide into the Unknown
Gerald A. Faich	531	Postmarketing Surveillance: Lessons Learned
John L. Turner	537	The Implementation of European Community Directives Concerning GMP
Ronald D. Mann	545	Monitoring Safety with Particular Reference to the European Community
Léon Gauci	551	Meeting Summary Report: Biotechnology and Drug Development
C. Benichou **G. Danan**	565	Guidelines for the Management of Adverse Events Occurring During Clinical Trials
Charles F. Curran **Larry M. Hagerman**	573	A System for Managing Medical and Technical Information
Betty R. Kuhnert	579	International Approval Process for Clinical Documents

Harold K. Pickering	585	In-House Mechanisms for Handling Products Liability Litigation
Yves Juillet	591	Industry Health Authorities Relationships in Pharmacovigilance (PMS): The French Situation
James D.Cope	595	Self-Care/Self-Medication: Where Are We Headed?
Annie L. Britt **Deanne E. Knapp** **Charles Anello** **Zollie A. Perry**	599	Completeness of Adverse Drug Experience Reporting by Manufacturers to the FDA
Albert Weissman	607	Inferring Drug Efficacy Based on Data from One Subject
	I	Software Survey Section
	V	Volume 25 Contents and Author Index